1. Switzerland Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Tecan Group AG

Tecan Group AG

246.20
CHF
-5.60
(-2.22%)
2.00BMarket Cap
Mar 16Next Earn
Tecan Group AG
LSE:0QLN
(London Stock Exchange)

Recent

price

246.20

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CHF
35.52
35.05
36.15
35.37
36.01
38.88
44.01
47.2
50.58
53.8
61.24
77.43
89.98
84.13
73.18
69.69
- -
Revenue per Share
1.55
4.42
3.92
4.16
3.63
5.05
4.74
5.67
6.02
6.18
8.69
9.95
9.53
10.34
5.3
-8.74
- -
Basic EPS, GAAP
4.79
2.89
-1.07
0.74
2.3
7.45
9.08
6.86
5.66
6.33
14
10.64
7.24
9.84
9.23
8.11
- -
Free Cash Flow per Basic Share
1
1
1.25
1.5
1.5
1.49
1.75
1.75
2
2.1
2.2
2.26
2.8
2.9
3
3
- -
Dividend per Share
21.22
24.89
26.94
30.34
32.37
38.43
42.24
47.16
52.05
55.52
61.35
96.61
106.64
105.52
112.79
90.98
90.71
Book Value per Share
17.75
21.3
23.28
25.96
23.8
28.75
27.97
33.08
34.27
36.74
43.46
6.87
18.04
25.63
28.77
26.78
23.39
Tangible Book Value per Share
10
11
11
11
11
11
12
12
12
12
12
12
13
13
13
13
13
Basic Weighted Avg Shares
371
377
391
388
400
440
506
549
594
637
731
947
1,144
1,074
934
882
- -
Sales/Revenue/Turnover
15.1
13.6
13.48
14.11
14.32
15.21
13.46
14.63
14.9
13.91
16.67
15.1
12.92
12.66
8.09
5.44
- -
Operating Margin (%)
9
9
10
10
10
16
21
25
22
34
38
59
67
71
67
61
- -
Depreciation Expense
16
48
42
46
40
57
55
66
71
73
104
122
121
132
68
-111
- -
Net Income, GAAP
19.18
16.14
19.67
17.7
18.17
13.42
16.64
16.54
15.23
11.57
12.3
11.79
14.99
1.29
13.56
- -
- -
Effective Tax Rate (%)
4.37
12.62
10.83
11.76
10.07
12.98
10.77
12.02
11.91
11.49
14.19
12.85
10.59
12.29
7.24
-12.54
- -
Profit Margin (%)
176
216
248
282
299
355
393
449
433
458
553
365
467
554
325
423
371
Working Capital
1
2
3
2
3
4
10
8
1
34
28
301
293
304
60
208
204
LT Debt
228
268
294
336
361
441
487
550
612
659
734
1,225
1,358
1,349
1,435
1,151
1,118
Total Equity
18.26
16.44
14.54
13.83
12.87
13.78
11.66
12.31
12.53
11.65
14.1
10.9
7.73
7.96
3.76
- -
- -
Return on Invested Capital (%)
7.09
18.86
15.02
14.41
11.43
14.07
11.59
12.52
12.11
11.25
14.15
10.85
7.64
8.01
4.12
- -
- -
Return on Capital (%)
7.52
19.19
15.09
14.5
11.53
14.25
11.75
12.71
12.16
11.51
14.89
12.42
9.38
9.76
4.86
-8.56
- -
Return on Common Equity (%)

Capital Structure

CHF

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
261
10
10
LT Borrowings
- -
150
151
LT Finance Leases
61
58
53
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
13
13
12
Market Capitalization
2,064
1,620
2,003

Working Capital

CHF

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
813
712
653
Cash, Cash Equivalents & STI
397
311
224
Accounts Receivable, Net
125
127
131
Inventories
215
213
219
Total Current Liabilities
506
289
282
Payables & Accruals
- -
- -
- -
ST Debt
261
10
10
Deferred Revenue
- -
- -
- -

Growth Rates

CHF

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.75%
12.76%
-19.78%
Free Cash Flow
8.53%
-6.79%
-12.89%
Net Income, GAAP
-21.76%
-57.27%
-263.53%
Sales/Revenue/Turnover
7.93%
5.14%
-5.54%
Total Cash Common Dividend
8.82%
8.18%
-0.76%

Semi-annual Revenue

CHF

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
934
2025
- -
- -
882
2026
- -
- -
- -

Semi-annual Earnings Per Share

CHF

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
5.3
2025
- -
- -
-8.74
2026
- -
- -
- -

Semi-annual Dividends Per Share

CHF

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
3
2025
- -
- -
3
2026
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Tecan Group AG Tecan Group AG develops, manufactures and markets automated laboratory instruments, workflow solutions and components primarily for life sciences research, biopharmaceuticals, forensics, applied markets and clinical diagnostics. The company offers liquid handling and robotics platforms including the Fluent, Freedom EVO, Veya and Duo systems; analytical benchtop readers and washers; microarray products such as scanners and hybridization stations; HP D300 digital dispensers; sample management systems; immunoassay reagents for infectious diseases, autoimmunity, neurodegeneration, endocrinology and food intolerance; smart consumables like disposable tips, microplates and reagent troughs; software packages such as FluentControl; and OEM services through Synergence, Cavro and Paramit brands encompassing custom instruments, components and contract manufacturing. Tecan operates globally with primary revenue from the Americas and Europe, supplemented by presence in Asia-Pacific including sites in China, Singapore, Australia and Malaysia, as well as Europe and the US; the company, founded in 1980, maintains headquarters in Männedorf, Switzerland. Recent developments include the acquisition of ELISA immunoassay assets from Cisbio Bioassays in April 2025 to expand specialty diagnostics offerings; a partnership with Grifols announced in Q1 2025 for biomarker panels leveraging single molecule counting technology; new manufacturing contracts such as one with a global diagnostics firm via Paramit and expanded production of a proteomics platform; a collaboration with a MedTech firm in women's health advancing to deliveries from Penang by end-2025; and shipments commencing for a next-generation diagnostic instrument family developed with a key Synergence partner.

Company News

Company News APIChatGPT

  • globenewswire.com

    Update zum 1. Quartal 2026: Tecan auf Kurs mit Umsatzwachstum im niedrigen einstelligen Bereich in Lokalwährungen; Ausblick für das Gesamtjahr 2026 bestätigt

  • globenewswire.com

    Q1 2026 Update: Tecan on track with low-single-digit local currency growth in Q1; full-year 2026 outlook confirmed

  • globenewswire.com

    Camila Japur joins Tecan as Chief Financial Officer

  • globenewswire.com

    Tecan presents 2025 results and provides details on program to reignite profitable growth

  • globenewswire.com

    Tecan präsentiert Ergebnisse 2025 und stellt Programm zur Rückkehr zu profitablem Wachstum vor

  • globenewswire.com

    Tecan meldet Rückkehr zum Umsatzwachstum und starken Auftragseingang im zweiten Halbjahr 2025

  • globenewswire.com

    Tecan reports return to sales growth and strong order entry in the second half of 2025